spacer
home > pmps > spring 2007 > outsourcing – know the risks
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Outsourcing – Know the Risks

Although it remains a growing trend, Juval Aviv of Interfor assesses the potentially harmful risks associated with outsourcing and the impact they could have on the pharmaceutical industry

Outsourced manufacturing has continued to grow exponentially over the past 20 years, becoming the standard business model for the pharmaceutical industry. At first, these companies provided access to resources not available internally or to additional resources during peak times. Today, however, outsourced manufacturing is a given. It is estimated that the US market for outsourced manufacturing is growing at the rate of 10 to 12 per cent annually, with many companies even outsourcing sales, data processing and computer operations. Smaller companies couldn’t exist without it and even larger, more established companies have turned to outsourced manufacturing to improve the bottom line.

RISK FROM COUNTERFEITERS

Before outsourcing is even considered, you have to be aware that you will be exposing your supply chain to tremendous risk from counterfeiters. Counterfeiting is a considerable and growing problem for the pharmaceutical industry and a danger to the public. Whether or not you choose to outsource, counterfeiting is a problem for every pharmaceutical company. However, sharing product information with third parties obviously increases the risks dramatically.

It is often incorrectly assumed that counterfeit pharmaceuticals are predominantly a problem for developing countries. However, with soaring healthcare costs and the increasing ease of purchasing pharmaceuticals online without a prescription, the problem is reaching countries with developed drug policies and regulations – including the US and the UK. Internet sales are a particular problem as most of the drugs come from unauthorised secondary wholesalers, selling products from counterfeiting hotspots such as Mexico, China and India.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Juval Aviv holds an MA in Business from Tel Aviv University and is President and CEO of Interfor, Inc. Before founding Interfor, Juval served as an officer in the Israel Defense Force, leading an elite Commando/Intelligence Unit, and was later selected by the Israeli Secret Service (Mossad) to participate in a number of intelligence and special operations in many countries in the late 1960s and 1970s. He has personally solved numerous cases of fraud, illegal short-selling, embezzlement and anti-competitive behaviour. Juval is the author of Staying Safe: The Complete Guide to Protecting Yourself, Your Family, and Your Business, 2004. He has also been a frequent contributor to articles and programmes on US preparedness relative to various forms of terrorism. Additionally, Juval serves as a consultant on counterterrorism for the FOX News Channel and has appeared on ABC’s ‘Nightline’, CNN, MSNBC and in numerous national and international newspapers and magazines.
spacer
Juval Aviv
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder


More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

INTERPHEX 2020

15-17 July 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement